Development of the treatment for autoimmune disorders using human tolerogenic dendritic cells induced by protein kinase C inhibitor.

2016 Fiscal Year Final Research Report

• Project/Area Number: 26860752
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Collagenous pathology/Allergology
• Research Institution: Ehime University
• Principal Investigator: Matsumoto Takuya 愛媛大学, 医学部附属病院, 講師(病院教員) (70724780)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 免疫寛容樹状細胞

Outline of Final Research Achievements

Previously, we reported that we could induce tolerance dendritic cell (tDCs) which had strong immune tolerance ability with the stability in the condition of the inflammatory environment by using C kinase inhibitors (PKCI) in the maturity process of the dendritic cell of human. In addition, we made a comparison between PKCI-tDCs and tDCs derived other materials, PKCI-tDCs was shown to be superior effects than other tDCs. Also PKCI-tDCs could be derived from the peripheral blood of the patient with collagen diseases (Sjogren's syndrome and rheumatoid arthritis). From these results mentioned above, PKCI-tDCs might have useful possibility in clinical application.

Free Research Field

リウマチ膠原病学